# Brain Metastases In ErbB2-Positive Breast Cancer

> **NCT00437073** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 22 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** capecitabine
- **DRUG:** topotecan
- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00437073
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2009-01
- **Final completion:** 2010-02
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues.
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437073, "Brain Metastases In ErbB2-Positive Breast Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00437073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*